Pacira BioSciences Inc. overcame investor allegations tied to statements about the strength of its patent fight for its top-selling painkiller while the biotech company was suing a competitor.
The pension fund leading the case didn’t sufficiently allege Pacira and executives disbelieved optimistic statements about the litigation, a New Jersey federal judge said in an unpublished opinion dismissing the lawsuit with finality Friday.
The Western Pennsylvania Teamsters and Employers Pension Fund’s theory contended that a negative claim construction ruling undercut Pacira’s patent for its non-opioid painkiller, and thus “continued expressions of confidence or uncertainty regarding the ultimate outcome of the case ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.